BioCryst Pharmaceuticals Inc
BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to… Read more
BioCryst Pharmaceuticals Inc - Asset Resilience Ratio
BioCryst Pharmaceuticals Inc (BCRX) has an Asset Resilience Ratio of 35.98% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2025)
This chart shows how BioCryst Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. Compare with other companies' asset resilience ratios.
Liquid Assets Composition Over Time
This chart breaks down BioCryst Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $185.01 Million | 35.98% |
| Total Liquid Assets | $185.01 Million | 35.98% |
Asset Resilience Insights
- Very High Liquidity: BioCryst Pharmaceuticals Inc maintains exceptional liquid asset reserves at 35.98% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
BioCryst Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare BioCryst Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
PINK:BIOVF |
Drug Manufacturers - Specialty & Generic | -0.02% |
|
Dongwha Pharm.Co.Ltd
KO:000020 |
Drug Manufacturers - Specialty & Generic | 1.92% |
|
Shenzhen Neptunus Bioengineering Co Ltd
SHE:000078 |
Drug Manufacturers - Specialty & Generic | 0.46% |
|
Yuhan Corp Preferred
KO:000105 |
Drug Manufacturers - Specialty & Generic | 0.99% |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153 |
Drug Manufacturers - Specialty & Generic | 1.81% |
|
Kotra Industries Bhd
KLSE:0002 |
Drug Manufacturers - Specialty & Generic | 9.82% |
|
Yuyu Pharma
KO:000220 |
Drug Manufacturers - Specialty & Generic | 1.74% |
|
Ildong Holdings Co Ltd
KO:000230 |
Drug Manufacturers - Specialty & Generic | 1.57% |
Annual Asset Resilience Ratio for BioCryst Pharmaceuticals Inc (1999–2025)
The table below shows the annual Asset Resilience Ratio data for BioCryst Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 35.98% | $185.01 Million | $514.16 Million | -8.09pp |
| 2024-12-31 | 44.07% | $216.14 Million | $490.42 Million | -9.77pp |
| 2023-12-31 | 53.84% | $278.34 Million | $516.96 Million | +32.11pp |
| 2022-12-31 | 21.74% | $119.54 Million | $550.00 Million | +21.19pp |
| 2021-12-31 | 0.55% | $3.21 Million | $588.15 Million | -7.89pp |
| 2020-12-31 | 8.44% | $28.24 Million | $334.71 Million | -4.15pp |
| 2019-12-31 | 12.58% | $22.05 Million | $175.28 Million | -40.36pp |
| 2018-12-31 | 52.94% | $77.74 Million | $146.84 Million | +16.97pp |
| 2017-12-31 | 35.97% | $64.11 Million | $178.26 Million | -0.26pp |
| 2016-12-31 | 36.22% | $32.55 Million | $89.85 Million | +18.03pp |
| 2015-12-31 | 18.20% | $22.66 Million | $124.56 Million | +4.88pp |
| 2014-12-31 | 13.32% | $18.23 Million | $136.87 Million | -21.25pp |
| 2013-12-31 | 34.57% | $16.89 Million | $48.87 Million | +8.96pp |
| 2012-12-31 | 25.61% | $14.71 Million | $57.44 Million | -5.14pp |
| 2011-12-31 | 30.74% | $25.27 Million | $82.21 Million | -5.73pp |
| 2010-12-31 | 36.47% | $40.32 Million | $110.57 Million | +16.89pp |
| 2009-12-31 | 19.58% | $27.84 Million | $142.19 Million | -26.69pp |
| 2008-12-31 | 46.27% | $39.19 Million | $84.69 Million | +32.58pp |
| 2007-12-31 | 13.69% | $19.54 Million | $142.72 Million | -34.55pp |
| 2006-12-31 | 48.24% | $33.04 Million | $68.49 Million | +26.98pp |
| 2005-12-31 | 21.26% | $21.10 Million | $99.25 Million | -22.89pp |
| 2004-12-31 | 44.15% | $14.33 Million | $32.47 Million | +17.28pp |
| 2003-12-31 | 26.87% | $8.09 Million | $30.10 Million | +1.15pp |
| 2002-12-31 | 25.72% | $10.62 Million | $41.30 Million | +3.52pp |
| 2001-12-31 | 22.20% | $13.12 Million | $59.10 Million | -0.64pp |
| 2000-12-31 | 22.84% | $16.18 Million | $70.83 Million | +3.09pp |
| 1999-12-31 | 19.75% | $14.50 Million | $73.40 Million | -- |